SUBJECT INDEX

A

Abetalipoproteinemia, 352, 356–58, 360–62, 365
Acetyl-CoA carboxylase, 213–15, 223, 226
  cDNA clone for, 220–21
  deficiency, 222
  phosphorylation of, 218–19
  regulation of, 215–19
β-N-Acetyl-D-glucosaminidase, 530
Acetylation
  amino-terminal, 463–64
  of internal amino acids, 464–68
Acetylcholine, 495–96
Acetylcholinesterase, 530–31
Acidemia
  organic, 222
Acidosis, 138
  in the alcoholic, 132–33
Action spectra
  for the formation of previtamin D_3, 380–82
  for previtamin D_3, 385
Ad libitum feeding
  and diet/cancer studies, 176–77
Adenine
  and lymphocyte growth, 90, 94
Adenylate cyclase
  odorant regulation of, 30
  and olfactory transduction, 28–29
  in taste epithelium, 37
Adipose
  in Zucker fatty rats, 158
Adipose tissue
  and cachectin, 595–96
Aflatoxin B_1
  and cancer, 101, 102, 107, 108
Aging
  and vitamin D, 390
  and previtamin D_3, 383, 390
Albumin
  and chromium absorption and transport, 555–56
  and copper transport in the blood, 239
  human serum, 290–91
Alcohol
  and carcinogenesis, 99–113
  and DNA metabolism, 110
  and nitrosamine metabolism, 108–9
Alcoholics
  and phosphate supplementation, 138
  Wernicke disease and Korsakoff psychosis in, 503–4
Alcoholism
  and magnesium depletion, 442
  and phosphate depletion, 132–33
  and thiamin deficiency, 500–501
Aldehyde oxidase, 402, 406–7
Aluminum salts
  and hyperphosphatemia, 125, 140
Ames Salmonella-mutagenesis assay, 107
Amino acid(s)
  acetylation of internal, 464–68
  binding sites
    and olfactory receptors, 26
    in catfish taste epithelium, 35
  and biotin, 213–14
  and chromium, 555, 556
  of egg white riboflavin-binding protein, 282, 283
  fetal accretion of, 52
  fetal catabolism of, 56, 57
  fetal interorgan cycling of, 51–52
  and fetal nutrition, 51–53, 54
  and lymphocytes, 87–88
  metabolism of sulfur-containing, 407, 408
  and milk synthesis, 68
  and stimulation of adenylate cyclase in olfaction, 30
  and thiamin deficiency, 496–97
  in total parenteral nutrition solutions, 129, 246
  in vitamin-K-dependent proteins, 569–71
Amino-terminal acetylation, 463–64
Amino terminus
  peptide acylation at, 469–71
Ammonia production
  by the placenta, 51
Amniotic fluid
  fetal swallowing of, 52–53
Anemia
  and cachectin, 598
  and copper deficiency, 241, 242, 245, 247
Antacid treatment
  and phosphate supplementation, 139
Antacids
  and phosphate depletion syndrome, 131
Anticonvulsants
  and biotin, 212, 225
Antiepileptic drugs, 444
Antithiamins, 490–91
Arachidonic acid, 518, 519, 521–22
Arterial disease
  and copper deficiency, 248
Arteriovenous differences
  and fetal metabolism studies, 45–46
Arthritis
  and copper deficiency, 248
Ascorbic acid
  and chromium, 555
Aspartate, 496–97
  synthesized within the fetus, 51
Ataxia
  and vitamin E deficiency, 359
Atherosclerotic disease
  and chromium, 545, 547
ATPase
  and n-3 fatty acids, 531
Avian riboflavin-binding proteins, 281–90
Avian riboflavinuria, 288–89

B

Babies
  premature
    and copper, 252–53
Bardet-Biedl syndrome, 260, 261
Barrett's syndrome, 111
Basal metabolic rate (BMR)
  and lactation, 76–77
Beer
  and cancer, 101, 106
Beriberi
  and thiamin, 483–85, 488, 501–2
  wet and dry, 484–85

Bile
  and copper, 239–40
  lithogenic index of, 314–15
Bile acids
  binding of, 306–7
  and carcinogenesis, 180
  and colon cancer, 175
Biochemical efficiency
  of milk synthesis, 68–71, 72
Biotin
  and lymphocyte growth, 89, 92
  deficiency, 212
  dietary requirement for, 212–13
  enzymes, 211–26
    four, 213–15
    recombinant cDNA for, 220–21, 226
  intestinal absorption of, 213
Biotin holocarboxylase synthetase, 223–24, 226
Biotinidase, 224–26
Bitter taste transduction, 34–35
Bleeding
  and vitamin K, 574
Blood
  chromium in, 552, 554
  fetal
    and turnover of CO2, 46
  and hypophosphatemia, 134–35
  macromolecules in, 334
  molybdenum in, 416
  of the phosphate-depleted patient, 135
  phosphate in, 123
  pterins in, 195–96
  umbilical
    and fetal metabolism studies, 45–46
Blood cells
  copper in, 251
Blood coagulation
  and vitamin-K-dependent proteins, 566, 569, 573
  and warfarin and vitamin K treatment, 574–77, 579–80
Body fat
  genotype-environment interaction in, 270, 274
  and multifactorial inheritance, 262–71
  percentage, 268, 274
Body fatness
  genetic indicators, 262–69
Body mass index (BMI), 259, 269, 273, 274
  and obesity, 262–65
Bone disorders
  and vitamin D deficiency, 388–89
Bone Gla protein (BGP), 565–66
  and osteoid mineralization, 578–79
  structure and properties of, 566–73
  synthesis
    and warfarin, 573–76, 579–80
Bone metabolism
  and magnesium, 438
Bones
  human
    phosphate in, 122, 140
Brain
  development, 521–22
  dietary docosahexaenoic acid incorporated into, 522, 533
  and n-3 fatty acids, 517–34
  in ob/ob mice, 152
  and thiamin, 483–85, 488–89
  in Zucker fatty rats, 158
Bran
  diverticular disease, 314
Breast cancer
  and alcohol, 101
Breast feeding
  and incidence of disease, 343
Breast milk
  "breast milk intoxication," 502
  and intestinal maturation, 343
Bureaucratic interests
  and nutrition policy, 4–5
Butylated hydroxyanisole (BHA)
  and carcinogenesis, 167
Butylated hydroxytoluene
  and carcinogenesis, 168

C

Cachectin, 585–603
  and adipose tissue and fat metabolism, 595–96
  and food intake and weight loss, 593–94
  history of, 586–89
  and interleukin 1 and other cytokines, 592–93
  and leukocyte populations and erythropoiesis, 597–98
  and the liver, 596–97
  production in disease states, 600–602
  protein structure and gene sequence, 589–90
  regulation of synthesis, 591–92
  and shock, 599–600
  and skeletal muscle protein metabolism, 594–95
  and wound healing and tissue repair, 598–99
Calcium
  and carcinogenesis, 176, 180
  and colon cancer, 175
  and dietary fiber, 305–6
  infusion, 453
  and intestinal phosphate absorption, 125
  and magnesium deficiency, 437, 447
  in serum, 436, 437
Caloric restriction
  of GTG-obese mice, 156
Calorie effect
  and carcinogenesis, 176–179
Calorimetric efficiency
  of milk production, 71–72
Cancer
  and contaminants in alcoholic beverages, 106
  and dietary fat, 167–80
  see also Carcinogenesis
Carbohydrate(s)
  altered dietary
    and insulin receptors, 160
  and fetal nutrition, 48–50
  for growth of lymphocytes, 87
  and lactation, 77–78
Carbon dioxide
  fetal, 46–48
Carboxylase
  acetyl-CoA, 213–19, 226
  β-methylcrotonyl-CoA, 213–15, 223, 226
  deficiency, 221–23
  propionyl-CoA, 213–15, 221, 223, 226
  pyruvate, 213–15, 219–21, 223, 226
γ-Carboxylase
  vitamin-K-dependent, 569–73
γ-Carboxylation
  of bone Gla protein, 573–74, 576
Carcinogenesis
  and alcohol, 99–113
  and dietary fat, 167–80
  and microsomal enzyme induction by ethanol, 107–8
  mechanisms by which ethanol enhances, 104, 106–10
  two-stage model for, 168
Cardiac arrhythmias
  and magnesium depletion, 447–49
Cardioplegic solutions
  magnesium in, 449–50
Carnosine
  in olfactory neurons, 24

Carter administration
and nutrition policy, 3, 4, 7
Cartilage
mineralization of growth plate, 578
Cation binding
and fiber, 305–6
Cells
M, 332, 336
in mammalian taste buds, 32
in olfactory epithelium, 22–23
Central nervous system (CNS) diseases and thiamin, 490
Central nervous system function, 492–500
Cerebellum
and vitamin E, 355
Cerebral oxidative metabolism, 48
Cerebrospinal fluid (CSF)
and hyperphenylalaninemia, 189
and 6-pyruvoyl tetrahydropterin synthase deficiency, 190
pterins in, 196–97
Ceruloplasmin, 237, 238, 240, 246, 250–51, 253, 254
Cholestasis
chronic childhood, 366–67
and vitamin E deficiency, 356–58, 360–65
Choline
and lymphocyte growth, 90, 94
Chromium
absorption of dietary, 555
in blood, 552, 554
in body tissues, 545, 554
deficiency, 545–47, 551
dietary intake, 557–58
evidence it is essential, 544–51
in hair, 553–54
in human nutrition, 543–58
in lipid metabolism, 547–48
measurement in the body, 551–54
metabolism and function, 554–57
supplemental trials, 548–51
transport, 555–56
in urine, 552–53, 554
Cirrhosis
of the liver, 100, 111, 112
Citrate
and acetyl-CoA carboxylase, 218
and magnesium depletion, 441
Coenzyme A
and pantothenic acid, 461–77
Collagen
and copper deficiency, 252
defects in, 238, 241
Colon
diverticular disease of, 313–14
Colon cancer, 169–70, 178
and dietary fat, 174–76
Communication
between scientists and policymakers, 11–13, 16–17
Conference on Food, Nutrition, and Health, 4
Congress
communication of scientific information to, 12–13
Congressional hearings
and policy formation, 6–7
Constipation
and dietary fiber, 316
Copper
biological roles of, 326–38
deficiency in animals, 240–44
deficiency in humans, 235–40, 244–54
homeostasis and transport of, 238–40
and human genetic diseases, 244–45
mild chronic deficiency, 247–52
severe deficiency, 245–46
Coronary artery disease, 444–47
and chromium, 547
Coronary artery spasm
and magnesium depletion, 447, 449
Coronary artery tone
and magnesium, 449
Crohn's disease
and dietary fiber, 315–16
Cyclic adenosine monophosphate
and intracellular effects of hormones, 123
Cyclic nucleotide-dependent protein kinase
and olfaction, 29–30
Cystic fibrosis
and vitamin E deficiency, 356–58
Cytochrome oxidase
deficiencies of, 241, 243, 244
genetic defects of, 238
severe reduction of, 241
and white blood cells, 251
Cytochrome P-450
and carcinogenesis, 107, 108
inhibition of, 170
Cytokines
and cachectin, 592–93

D

Dairy products
and colon cancer, 175
Decision-making approaches
of politicians and scientists, 8–11
Decision-making criteria
in nutrition policy, 3–8
Depigmentation
and copper deficiency, 238, 243–44, 245
Diabetes
hemochromatosis, 551
and magnesium, 442
Diabetes mellitus
and chromium, 545, 550
and phosphate loss, 132, 141
Diabetic ketoacidosis
and phosphate dosage, 138
Diabetics
hair chromium in, 553
plasma chromium levels in, 552
Dialysis patients
with hyperphosphatemia, 138–39
Diarrhea
and copper deficiency, 245, 246
and treatment with phosphate, 138
Diet
and chromium, 557–58
Dietary guidelines
controversy surrounding national, 9–10
published by USDA and HHS, 7
Digestion
and dietary fiber, 307–9
lysosomal, 339
Dihydrobiopterin synthetase (DHBS), 190
Dihydroneopterin, 190
Dihydropteridine reductase deficiency, 188, 191
and BH_4 loading test, 198
and blood and serum analysis, 195–96
and enzyme assays, 197–98
prenatal diagnosis of, 198, 199
and pterins in cerebrospinal fluid, 196–97
and pterins in tissue, 196
therapy, 200
and urinary analysis, 195
Dimethylbenz[*a*]anthracene (DMBA)
in carcinogenesis experiments, 169–74

Dimethylnitrosamine (DMN)
and carcinogenesis, 104–10
Disease states
production of cachectin in, 600–602
DNA, 596–97
and histones, 464–67
metabolism
and alcoholism, 110
repair
effects of alcohol on, 110
technology
and obesity, 273–74
in thiamin-deficient rats, 498
cDNA
of cachectin, 589–90
recombinant
and biotin enzymes, 220–21, 226
sequence
and MGP, 567, 568–69
Docosahexaenoic acid (DHA), 517n, 518, 521
accumulation during development, 521–22
in cerebral gray matter, 519
depletion of, 523–28
dietary, 522, 533
functional effects in membranes, 528–32
lipoxygenase products of, 531–32
in the retina, 520–21
tissue distribution of, 519–20
Dopamine-β-hydroxylase deficiency, 243, 244, 249
Down's syndrome, 261

E

Earle's balanced salt solution, 86
Economic interests
and nutrition policy, 3–4
Eczema
and intestinal permeability, 338, 339
and macromolecular absorption, 344
Egg white
and riboflavin-binding protein, 281–84, 286–88
Egg yolk
riboflavin-binding protein, 281, 285, 287, 288
Eicosapentaenoic acid (EPA), 517n, 518
Elastin
defects in, 238, 241
Elderly
and chromium, 549
and vitamin D deficiency, 394–95
vitamin D levels in, 392–93
Embryo(s)
chick
metabolism by, 288
riboflavin requirements of, 293
supplying nutrients to, 280
Endocytotic mechanisms
and macromolecule transport, 342
Energy costs
of lactation, 63–78
Energy expenditure
and cancer risk, 178–79
Enzyme activity
and carcinogenesis, 107–8, 110
and n-3 fatty acids, 530–31
Enzyme assays
and BH_4 deficiency, 197–98
Enzyme systems
and thiamin diphosphate, 487
Enzymes
biotin, 211–26
of biotin metabolism, 223–26
copper, 236–38, 249–52
molybdenum-containing, 402
in the pentose phosphate pathway, 494–95
Epidemiologic studies
of alcohol and cancer, 100–101
Epidemiology
and controversy, 9
for vitamin D, 388–93
Epithelium
gustatory
organization of, 31–32
olfactory
cellular organization, 22–23
Epsom salts, 451
Erythropoiesis
and cachectin, 597–98
Esophageal cancer
and alcohol, 100, 106
and dietary fat, 168, 169
Esophageal carcinogenesis
and alcohol, 110–11
Esophageal DNA
and ethanol, 109
Ethanol
and carcinogenesis experiments, 101–5
its induction of microsomal enzymes and carcinogenesis, 107–8
Ethanol consumption
increased cancer risk associated with, 168
Ethanol ingestion
maternal, 53
Exercise
and carcinogenesis, 179
Extrahepatic carcinogenesis
effects of ethanol on, 102, 104, 105

F

Fanconi's syndrome, 133
Fasting
and insulin receptors, 161
maternal
and fetal amino acid accretion and uptake, 52
maternal
uteroplacental and fetal response to, 55–57
of ob/ob mice, 153
Fat(s)
amount of subcutaneous, 265–68, 274
deposits
and human reproduction, 64
dietary
and cancer, 167–80
and initiation of carcinogenesis, 168–71
and tumor promotion, 17
distribution
regional, 268–69, 274
and fetal nutrition, 53–55
of GTG-obese mice, 156
in human milk, 67
and lactation, 77–78
malabsorption disorders
and vitamin E deficiency, 352, 356–59, 368
mass
and body fat percentage, 268, 274
metabolism
and cachectin, 595–96
and milk synthesis, 69–70
in ob/ob mice, 152
patterning
subcutaneous, 269, 274
stores
in support of lactation, 73–75, 78
tissues
vitamin D built up in, 391–92
Fatty acetyl-CoA
and acetyl-CoA carboxylase, 218
Fatty acid(s)
accumulation during development, 521–22
dietary deficiency, 523–28
and enzyme activity, 530–31
and milk synthesis, 68–69
n-3, 517–34
polyunsaturated
and vitamin E, 353

RDA, 533
short-chain metabolism and utilization 311–12
Fatty acid acylation
of peptides, 468–69
Fatty acid synthesis
and acetyl-CoA carboxylase, 215, 216
Fetal metabolism
methodology of study of, 44–48
Fetal nutrition, 43–57
and amino acids, 51–54
and carbohydrates, 48–50
and fats and lipids, 53–55
Fetal warfarin syndrome, 578
Fetuses
and n-3 fatty acids, 522
Fiber
analysis of, 303–4
and cation binding, 305–6
crude, 304
dietary, 301–19
adverse effects of, 317–19
anti-toxic effects of, 316–17
and availability of copper, 253
binding properties of dietary, 306–7
and carcinogenesis, 168
and colon cancer, 175
components of dietary, 303
and digestion, 307–9
and gastrointestinal disorders, 313–16
gastrointestinal effects of, 312
glycemia and dietary, 309–10
and lipidemia, 307
hydratability of, 305
transit time in digestion, 310–11
Fick principle
and fetal metabolism studies, 45–49
Fish oil
and tumor promotion, 179
Flavin adenine dinucleotide (FAD), 403
Food allergies, 332
and intestinal permeability, 338, 339
Food allergy, 344
Food intake
and cachectin, 593–94
in lactating women, 72–73, 78
Foods
with high copper content, 252
Fractures
increased risk of, 388–89, 394, 395
Fructose
and copper, 253–54
and fetal nutrition studies, 49–50
and lipogenesis, 216

G

Gallstones
and dietary fiber, 314–15
Gamma-aminobutyrate (GABA) glutamate, 495–97
Gastrointestinal absorption
of intact proteins, 329–45
Gastrointestinal diseases, 337, 338
Gastrointestinal disorders
and dietary fiber, 313–16
Gastrointestinal malabsorption
and hypophosphatemia and phosphate depletion syndrome, 131, 141
Gastrointestinal route
closure of, 342–43
Gastrointestinal tract
barrier function of, 330
fetal, 53
and hypophosphatemia, 135
as an immune organ, 335–37
and macromolecular absorption, 341
phosphate loading through, 139
Gene structure
of cachectin, 589–90
Genetic control
of enzyme synthesis, 405
Genetic diseases
and copper deficiency, 244–45
Genetic material
phosphate in, 123, 140
Glucose
in brain metabolism, 492
infusions
hypophosphatemia following, 130
lactose synthesis from, 68
and lymphocyte growth, 87, 93, 94
metabolism
and chromium, 547
tolerance
and chromium, 544–46, 548–50, 555–57
uptake
fetal, 47–50, 55–56
and the Fick principle, 45–46
uterine, 49, 56
utilization
fetal, 46–47, 49–50, 55, 56
Glutamate
synthesized within the fetus, 51
and thiamin deficiency, 496–97
Glutamic acid
and vitamin-K-dependent bone proteins, 566, 571–73
Gluten ingestion
and schizophrenia, 344
Glycemia
and dietary fiber, 309–10
Glycemic index, 310
Gold thioglucose
obesity induced by, 155–57
Guanosine triphosphate cyclohydrolase I (GTPCH), 188–89
and biosythesis of BH4, 186
deficiency
and enzyme assays, 197–98
prenatal diagnosis of, 199
and pterins in cerebrospinal fluid, 196
and urinary analysis, 194
Gustatory epithelium
organization of, 31–32

H

Hair
chromium in, 553–54
Heart
metabolic fuels of, 48
thiamin in, 488
Heart disease
coronary, 10
ischemic
"zinc-copper hypothesis" of, 249
Hemochromatosis
and chromium deficiency, 551
Hemodialysis
and biotin deficiency, 212
Hemolysis
and hyperphosphatemia, 139, 141
Hepatecellular carcinoma (HCC)
in alcoholics, 100–101
Hepatic carcinogenesis
effects of ethanol on, 102, 103
Hepatitis
in alcoholics, 100–101, 111–12
Hepatocellular carcinoma
in the alcoholic, 111–12
Heredity
and body fat, 259–74
HEW
"turf war" between USDA and, 5

High performance liquid chromatography (HPLC)
and BH_4 deficiency, 193–94, 196–98
Holocarboxylase synthetase
and biotin, 223–24, 226
deficiency, 222–23
Homeostasis
phosphate, 124–27
Hormone(s)
and intestinal closure, 343
vitamin D is, 376
Human Nutrition Research Center, 4
Hydratability
of fiber, 305
Hydroxyapatite
and bone Gla protein, 573–74, 575, 577
crystal growth of, 578
Hyperglycemia
and chromium, 545–46
and phosphate loss, 132, 141
Hyperkalemia, 138
Hyperlipidemia
and chromium, 547
Hypermagnesemia
and magnesium toxicity, 452–53
Hyperphenylalaninemia
and BH_4 loading test, 198
due to tetrahydrobiopterin deficiency, 188–92
neonatal, 193
Hyperphosphatemia, 138, 139–40, 141
and ectopic calcification, 139–40
management of, 140
Hypertension
and magnesium, 450
Hypertonic solutions
and intestinal permeability, 342
Hypocalcemia, 138, 436, 437, 440–42, 451
Hypokalemia, 436, 437, 440–42, 447
alcohol-induced, 132
in myocardial infarction, 447–48
Hypomagnesemia, 436, 437, 439, 441, 442, 447, 448
alcohol-induced, 132
post-parathyroidectomy, 444
preventive measures, 450
Hypomagnesuria, 437
Hypoparathyroidism
and hyperphosphatemia, 139
Hypophosphatemia
antacid-induced, 131
without cellular phosphate depletion, 127–28
clinical manifestations of, 133–37, 141
gastrointestinal and hepatic manifestations of, 135
and gastrointestinal malabsorption, 131, 141
hematologic manifestations of, 134–35
and large urinary losses, 133
metabolic manifestations of, 137
musculoskeletal manifestations of, 135–36
nervous system manifestations of, 134
and phosphate depletion syndrome, 128
renal manifestations of, 136
total parenteral nutrition-induced, 129, 130
treatment of, 137–39, 141

I

Ideological interests
and nutrition policy, 4
Immune organ
gastrointestinal tract as, 335–37
Immunity
passive
in animal species, 335
in humans, 335, 343
Immunoglobulins
riboflavin-binding, 291–92
Inositol
and lymphocyte growth, 90, 94
Insulin(s)
and lymphocyte growth, 93
maternal, 56
maternal and fetal, 50
and pyruvate carboxylase, 220
and synthesis of acetyl-CoA carboxylase, 216–17
Insulin receptors
and altered dietary carbohydrate, 160
and altered dietary lipids, 160–61
and altered dietary protein, 161
and fasting and refeeding, 161
and nutrition, 149–62
Interleukin 1
and cachectin, 592–93
Intestinal absorption
and alcohol consumption, 109
of biotin, 213, 225–26
of calcium, 390
of dietary calcium and phosphorus, 376
of dietary vitamin D, 390
of phosphate, 126
of thiamin, 489
of vitamin E, 354, 356, 358
Intestinal morphology
and dietary fiber, 313
Intestinal permeability
assessment of, 342
and intact protein absorption, 332
and intraluminal glucose, 340
measurement of human, 337–40
in schizophrenics, 344
Intestinal preparations
in vitro, 334–35
Intestinal tract
phosphate absorbed in, 124–25, 140
Intestinal transport
of magnesium, 430–31
Intestinal villi
and dietary fiber, 313
Intestines
as immune organs, 331
Intrauterine growth retarded infants (IUGR), 53
Ion channels
and taste transduction, 36–37
Iron
and chromium absorption, 555

J

"Joggers enteropathy," 338

K

Ketoacidosis
diabetic, 442
treatment of, 132
Ketoacids
and fetal nutrition, 53–54
in placental metabolism, 56
α-Ketoglutarate dehydrogenase, 484, 491, 492, 494, 495
Ketone bodies
uterine uptake of, 55
Kidney(s)
and copper homeostasis, 240
disease
and magnesium depletion, 443–44
and hyperphosphatemia, 139
and hypophosphatemia, 136
magnesium excretion through, 452
and phosphate conservation, 133
phosphate excretion through, 123, 140

Kinase
protein
and olfaction, 29–30

L

Lactate
and fetal nutrition studies, 49–50
placental production of, 51–52
Lactation
calculating energy costs, 65–66
copper content of breast milk during, 252
energy costs of, 63–78
energy-sparing adaptations during, 75–77, 78
human, 64–65
and increased food intake, 72–73, 78
and utilization of body fat stores, 73–75, 78
Lactose
in human milk, 67
and lactation, 77
and milk synthesis, 68
Latitudinal effect
on sunlight exposure, 385–86, 391
Laurence-Moon syndrome, 260
Lectins
and lymphocyte growth, 91
Leigh's syndrome, 504–5
Leukocyte populations
and cachectin, 597–98
Light sources
artificial
and vitamin D, 387–88
Lignin
binding capacity of, 306
Linoleate
and fetal nutrition, 54
Linoleic acid, 517, 518, 519, 522, 525
anticarcinogenic derivatives of, 170–72
and carcinogenesis, 173–76, 179
and fetal nutrition, 54
Linolenic acid, 517–19, 522, 524, 525, 528
Lipid
and insulin receptors, 160–61
metabolism
and chromium, 547–48
peroxidation
and n-3 fatty acids, 532
Lipidemia
and dietary fiber, 307
Lipids
and chromium, 549
and fetal nutrition, 53, 54–55
in the retina, 520–21
Lipogenesis
and acetyl-CoA carboxylase, 215
and dietary fructose, 216
Lipomas, 261
Lipoxygenase products
of docosahexaenoic acid, 531–32
Lithogenic index
of bile, 314–15
Liver
and acetyl-CoA carboxylase, 215–16
and cachectin, 596–97
cirrhosis of, 100, 111, 112
copper level in the fetal, 253
copper levels in, 249
of db/db mice, 154
disease
and vitamin E deficiency, 360–61
fetal, 51–52, 54
function
and extrahepatic carcinogenesis, 104
of GTG-obese mice, 155
and hepatopcellular carcinoma, 111–12
in ob/ob mice, 151–52
rat
molybdenum in, 416
sulfite-oxidizing capacity of, 407–8
thiamin in, 4
vitamin E stored in, 355
and vitamin K, 580
yolk-specific proteins produced by hen, 285–86
in Zucker fatty rats, 157
Lumazines, 186
Lymphocytes
activation and stimulation of growth, 91–92
and amino acids, 87–88
essential components for minimal media for, 85–90
growth requirements, 81–94
human
media for growth, 82–90
inorganic components in culture media for, 86–87
in ob/ob mice, 152
and vitamins, 88–90
Lymphoid tissue, 335
Lymphokines
and lymphocytes, 84–85
Lysyl oxidase
and copper deficiency, 245, 252
deficiency, 238, 241

M

Macromolecular absorption
and experimental manipulations, 334–35
and food allergies and skin diseases, 339
and gastrointestinal diseases, 337
and M cells, 336
routes and mechanisms for, 341–42
Macromolecular permeability, 345
tests for, 340
Macromolecular transport, 340
Macromolecules
in the blood, 334
radioisotope tracing of, 333
Magnesium
absorption, 430–31
and bone metabolism, 438
and coronary artery tone, 449
and disease development, 444–50
deficiency, 436–41, 451
depletion. 430, 441–44
dietary intake, 430
experimental and clinical depletion, 438–39
in health and disease, 429–53
homeostatic controls, 430–33
and hypertension, 450
RDA for, 435–36
renal regulation of, 431–34
repletion of, 440–41, 450–52
requirements of health, 433, 435–36
salts, 140, 452
in serum, 435, 438–40, 442, 443, 448, 450–53
therapy, 450–52
toxicity, 453
tubular absorption of, 431–32
Malabsorption
and magnesium, 442–43
Malnourished children
and chromium, 549
Malnutrition
and copper deficiency, 245–46
protein-energy
and magnesium depletion, 443
and thiamin deficiency, 489
Maple syrup urine disease
thiamin-responsive, 505–6
Maternal-fetal exchange
two-pool model of, 47
Matrix Gla protein (MGP), 565–66
and hydroxyapatite crystallization, 578

and osteoid mineralization, 578–79
structure and properties of, 566–73
Meat consumption
and colon cancer, 169–70, 175
Media
and the policymaking process, 13, 17
Melanin
and previtamin D_3 synthesis, 382
and vitamin D synthesis, 391
Membranes
and n-3 fatty acids, 528–32
and pantothenic acid, 475–77
Mendelian inheritance
of obesity, 260–61
Menkes disease, 240, 241, 243–46, 248, 249
Metallothionein, 253
and copper, 239, 240, 250
β-Methylcrotonyl-CoA carboxylase, 213–15, 223, 226
deficiency, 222
Microsomal enzymes
and carcinogenesis, 107–8
hepatic
and ethanol, 109
Milk
breast, 66–67
copper content in, 252
of primates, 64
Milk production
calculation of costs of, 66–72
calorimetric efficiency of, 71–72
Milk synthesis
costs of, 65–66
energy cost of, 68–72
Mineral balance
and dietary fiber, 305–6, 318–19
Minimal media
applications for, 92–93
Molybdenum, 401–25
biochemistry of, 402–14
in blood, 416
and carcinoma of the esophagus, 111
daily requirements, 417
deficiency, 401–2, 417, 419–21
dietary sources of, 416–19
in tissues, 415–16
toxicity, 421–22
Molybdenum cofactor, 410–14
deficiency, 412–13
in different tissues, 404
Molybdopterin, 413–14
and tissues, 415
Murine models
of inherited obesity, 151–55
Muscle(s)
of db/db mice, 154–55
of GTG-obese mice, 156
lesions
and vitamin E deficiency, 361, 363–64
in ob/ob mice, 152
and phosphate deprivation, 135–36
in Zucker fatty rats, 157–59
Muscular dystrophy
and vitamin E treatment, 352
Myelination
and copper, 243
Myocardial disease
and copper deficiency, 241–43, 249
Myocardial infarction
hypokalemia in, 447–48
and magnesium, 445–46
Myocardium
magnesium contents of, 446–47

N

National Dietary Goals, 3
National Nutrition Consortium, 16
National School Lunch program, 7
Nephrotoxic drugs
and magnesium depletion, 443–44
Nerve conduction
and thiamin, 497–98
Nervous system
vitamin E in, 355
Neurologic dysfunction
pathogenesis of, 364–65
Neurological disease
and vitamin E deficiency, 351–69
Neurological effects
of copper deficiency, 243, 244
Neurons
olfactory, 22, 23–25
Neurotransmitters
and thiamin deficiency, 495–97
Neutropenia
and copper deficiency, 241, 242, 245, 247
New Zealand Obese (NZO) mouse, 155
Nicotinamide adenine dinucleotide (NAD), 403–4
Nicotinic acid
and chromium, 555–57
Nitrate reductase, 410–11
Nitrogen
utilization of
and phosphate, 123
Nitrosamine metabolism
and alcohol, 108–9
and ethanol, 104
Nitrosamines
and cancer, 106, 107, 110
in carcinogenesis experiments, 102
5'-Nucleotidase
and n-3 fatty acids, 530
Nutrition policy, 1–18
and bureaucratic interests, 4–5
controversy and scientific consensus, 11
decision-making criteria, 3–8
and economic interests, 3–4
and ideological interests, 4
Nutrition research
grants for, 3
Nutritional repletion
and phosphate depletion syndrome, 128–30, 141

O

Obese subjects
starvation in, 439
Obesity
and body mass index, 262–65
in humans, 160
induced by gold thioglucose, 155–57
inherited
murine models of, 151–55
limitations of studies of, 271–73
Mendelian inheritance of, 260–61
rat models of, 157–59
research trends in, 273–74
Occipital horn syndrome, 244–45
Odorant interaction(s)
with membrane protein receptors, 27
with olfactory cilia, 25–26
Odorant regulation
of adenylate cyclase, 30
Oleic acid
and tumor promotion, 171, 174
Olfaction
biochemistry of, 21–31
Olfactory epithelium
cellular organization of, 22–23
Olfactory neurons, 22–25
Olfactory receptors
molecular characteristics, 25–27

Olfactory signal transduction, 22
  molecular mechanisms of, 27–31
Oocyte
  riboflavin in, 287–88
Oral cancer
  and alcohol and smoking, 100
Oral immunization, 336–37
Osteoblast
  bone Gla protein secreted from, 573, 574
Osteoid mineralization, 578–79
Osteomalacia
  and hypophosphatemia, 136
Osteoporosis, 388, 390, 394
  and copper deficiency, 241, 242, 244, 245, 247–48, 252
Oviduct
  and riboflavin-binding protein synthesis in hens, 286
Ovoflavoprotein, 280
Oxidation products
  and tumor promotion, 176
Oxygen uptake
  fetal, 48, 55–56
Ozone
  solar spectrum absorption coefficient, 384

P

Pancreatic cancer
  and alcohol, 101
Pancreatic carcinogenesis
  and alcohol, 104
Pantothenic acid
  and coenzyme A, 461–77
  and lymphocyte growth, 89, 92
  and membrane assembly and transport, 475–77
Parathyroid gland
  and magnesium depletion, 439–40
Parathyroid hormone
  and intestinal phosphate absorption, 124–25
  and magnesium depletion, 441
Parenteral nutrition
  and copper deficiency, 246
Parkinson's disease, 249
Pentose phosphate pathway, 494–95
Peptic ulcers
  treatment of, 131
Peptide acylation
  at the amino terminus, 469–71
  at internal sites, 471–75
Peptide drugs
  oral administration of, 332
Peptides
  and digestion, 330–31
  fatty acid acylation of, 468–69
Personality changes
  and magnesium deficiency 436–37
Peyer's patches
  in the small intestine, 335, 336
Phenylketonuria (PKU)
  treatment of, 188
Phosphate
  depletion
    and alcoholism, 132–33
    hypophosphatemia without, 127–28
    and starvation, 131–32, 141
    treatment of, 137–39, 141
  and diabetes mellitus, 132
  in human soft tissues, 122–23, 140
  intestinal absorption of, 124–25, 140
  in serum
    and magnesium depletion, 436, 438
  side effects of treatment with, 138
  and utilization of nitrogen, 123
  vs phosphorus, 122n
Phosphate binders
  and hyperphosphatemia, 125, 141
  and hypophosphatemia, 131, 141
Phosphate depletion syndrome (PDS)
  antacid-induced, 131
  causes of, 128–33
  and gastrointestinal malabsorption, 131, 141
  and hypophosphatemia, 128
  and total parenteral nutrition, 130
Phosphate-eliminating enzyme (PEE), 190
Phosphate homeostasis, 124–27
Phosphatidylethanolamine methyltransferase
  and n-3 fatty acids, 531
Phosphorus
  distribution and function in humans, 122–23, 140
  metabolism, 121–41
  vs phosphate, 122n
Photodegradation
  of vitamin D_3, 387, 394
Physical activity
  and lactation, 77
Pickwickian syndrome, 260, 261
Pigmentation
  and copper deficiency, 248–49
  and synthesis of vitamin D_3, 389
  and vitamin D, 382–83, 391
PKU
  and BH_4 deficiency, 193
  and biopterin levels, 189–90
  treatment of, 199–200
Placenta
  and fats and lipids in fetal nutrition, 53–55
  metabolic needs of, 49–50
  uses glucose, 48
Placental amino acid metabolism
  and the fetal liver, 51–52
Placental glucose transport, 49–50
Placental glucose uptake, 50
Placental glucose utilization, 47, 50, 56
Placental metabolism
  and fetal $^{14}CO_2$ excretion measurements, 48
Plasma
  chromium in, 552, 554
Policy making
  scientists' involvement in, 13–15
Policymakers
  communication between scientists and, 11–13, 16–17
  and scientists, 3–14
Policymaking process
  and controversy, 11, 15–16
  fear of involvement in, 13–14
  nonscientific factors in, 5–8, 14–15
Politicians
  decision-making approach of, 8–9, 11
Politics
  and science, 1–18
Potassium
  depletion, 447
  in serum, 437, 448
Prader-Willi syndrome, 260–61
Pregnancy
  and chromium, 551
Previtamin D_3
  action spectra for the formation of, 380–82
  and aging, 383, 390
  converted to vitamin D_3, 394
  synthesis
    and seasonal and latitudinal efficacy of the sun, 385–86
Primates
  and n-3 fatty acids, 526–28

Prisoners of war
refeeding syndrome in starved, 128–29
Propionyl-CoA carboxylase, 213, 214, 215, 223, 226
and biotinidase, 225
and recombinant cDNA, 221
Protein(s)
absorption, 329–45
altered dietary
and insulin receptors, 161
and availability of copper, 253
in breast milk, 66–67
G-protein(s)
and chemosensation, 38
and olfaction, 28, 29
and phospholipase C activation, 30–31
and lactation, 77–78
metabolism
in skeletal muscle, 594–95
and milk synthesis, 68
odorant-binding
and olfactory receptors, 26–27
and pantothenic acid and coenzyme A, 461–77
riboflavin-binding, 279–93
vitamin-K-dependent, 565–80
Protein-free minimal media
for growth of human lymphocytes, 85–90
Protein probes, 340
Protein structure
of cachectin, 589–90 ,
Provitamin D
photochemistry and photoisomers of, 377–78
Pterins
in the blood and serum, 195–96
in cerebrospinal fluid, 196–97
defined, 186
in tissue, 196
urinary, 194–95
Pyruvate
and lymphocyte growth, 90, 94
and thiamin, 485, 487, 492
Pyruvate carboxylase, 213–15, 223, 226
cDNA clone for, 221
deficiency, 505
regulation of, 219–20
Pyruvate dehydrogenase, 484, 491–95
6-Pyruvoyl tetrahydropterin 2'-keto reductase (PTPR)
and biosynthesis of BH4, 186–87
6-Pyruvoyl tetrahydropterin (PTP) reductase
and conversion of 6-pyruvoyl tetrahydropterin to BH_4, 191–92
6-Pyruvoyl tetrahydropterin synthase (PTPS)
and biosythesis of BH_4, 186
deficiency, 188–90
and BH_4 loading test, 198
and blood and serum analysis, 195–96
and enzyme assays, 197–98
prenatal diagnosis of, 199
and pterins in cerebrospinal fluid, 196–97
and pterins in tissue, 196
and urinary analysis, 194–95

R

Radioisotope tracing
of macromolecules, 333
Rat(s)
models of obesity, 157–59
and n-3 fatty acids, 523–26
Reagan administration
and nutrition policy, 4
Receptors
olfactory
molecular characteristics, 25–27
taste
molecular characteristics, 33–35
Rectal cancer
and alcohol, 104
and beer drinkers, 101
Rectal carcinogenesis
and ethanol, 112–13
Renal diseases
and copper, 254
Renal failure
and hyperphosphatemia, 139
Renal phosphate absorption, 125–26
Reproduction
human
and fat deposits, 64
Respiratory alkalosis
and hypophosphatemia, 127
Retina
docosahexaenoic acid in, 520–21
and n-3 fatty acids, 517–34
Rhabdomyolysis
and hyperphosphatemia, 139, 141
Rheumatoid arthritis
and macromolecular absorption, 344
Riboflavin
and lymphocyte growth, 89, 92–93
transport and disposition of, 292–93
transport in mammals, 289–90
Riboflavin-binding immunoglobulins, 291–92
Riboflavin-binding protein(s), 279–93
in egg-laying vertebrates, 289
egg white, 282–84
egg yolk, 285
mammalian, 290–93
pregnancy-specific, 292
serum, 284–85
Riboflavinuria
avian, 288–89
Rice
and beriberi, 484–85, 501
Rickets
development of, 394
and hypophosphatemia, 136
incidence of, 391
sunlight as a cure for, 376–77
and vitamin D deficiency, 388, 389
RNA, 596–97
and chromium, 557

S

Salty taste reception, 33
Schizophrenia
and gluten ingestion, 344
and intestinal permeability, 338, 339
and thiamin deficiency, 500–501
Science
and politics, 1–18
Scientific information
communicating, 11–13, 16–17
Scientists
decision-making approach of, 8–11
and involvement in policy making, 13–15
and policymakers, 3–14, 16–17
who influence nutrition policy, 18
Senate Select Committee on Nutrition and Human Needs, 3, 4
Sepiapterin reductase (SR)
and biosynthesis of BH_4, 186–87
and conversion of 6-pyruvoyl tetrahydropterin to BH_4, 191–92
Sepiapterin-synthesizing enzyme-1 (SSE1), 190
Serum
chromium in, 552, 554
copper in, 246, 250–51, 254

Serum-containing medium
for growth of human lymphocytes, 82
Serum-free medium
for growth of human lymphocytes, 82–90
Serum riboflavin-binding protein, 284–85
Shock
and cachectin, 599–600
Sickle cell anemia
and zinc, 236, 246
Signal transduction
olfactory, 22, 27–31
taste
molecular mechanisms, 36–37
Sister chromatid exchanges (SCEs), 110
Skeletal defects
and phosphate depletion, 136
Skin
formation of vitamin D in, 378–88, 394
Skinfold measurements
and subcutaneous fat, 265, 267–68
Smokers
and esophageal carcinogenesis, 111
Smoking
and cancer, 100
Sodium cyclamate, 317
Starvation
feeding after, 127–29
and phosphate depletion, 131–32, 141
tissue breakdown in, 131
Stomach cancer
and dietary fat, 169
Streptozotocin administration
in ob/ob mice, 153
in Zucker fatty rats, 158
Subacute necrotizing encephalomyelopathy (SNE), 504–5
Sudden infant death syndrome (SIDS), 506
Sugar
vitamin A fortification of, 6
Sulfite
effects of, 409
Sulfite oxidase, 402, 407–11, 415
deficiency, 402, 412
and molybdenum cofactor, 413–14
Sun
seasonal and latititudinal efficacy of, 385–86
Sunlamps, 388
Sunlight
as a cure for rickets, 376–77
spectral character of, 382
that reaches the Earth's surface, 384–85
and vitamin D, 375–95
Sunscreen(s), 393
and cutaneous production of previtamin D_3, 383
Superoxide dismutase
in blood cells, 251, 254
severe reduction of, 241
Sweet taste receptor, 34
Sweeteners
artificial, 34

T

Tannery workers
chromium levels in, 552, 553
Taste
biochemistry of, 31–38
signal transduction, 22
Taste buds
properties of, 32–33
transduce stimulus signals into cellular activity, 22
in the vertebrate oral cavity, 31–32
Taste signal transduction
molecular mechanisms, 36–37
12-*o*-tetradecanoylphorbol-13-acetate (TPA), 179
tumor promoter, 173
Tetrahydrobiopterin
biosynthetic pathway of, 186–87
deficiency
and hyperphenylalaninemia, 188–92
laboratory diagnosis of, 193–99
symptoms of, 192–93
prenatal diagnosis, 198–99
therapy, 200
treatment of, 199–200
Thermogenesis
and lactation, 77
postprandial
measurements of, 70–71
Thiamin
absorption of, 489
and beriberi, 483–85, 488, 501–2
biosynthesis, 485–87
biosynthetic role of, 498–99
and the brain, 483–506
and central nervous system function, 492–500
deficiency, 484
animal models of, 499
evaluation of deficiency, 491–92
and human diseases, 500–506
and nerve conduction, 497–98
RDA of, 488
subclinical deficiency, 500–501
toxicity, 506
transport across blood-brain barrier, 489–90
Thiamin diphosphate (TDP), 484, 495, 498, 505–6
and antithiamins, 490–91
biochemical role of, 487
in the brain, 488–89
effect, 491–92, 500, 501
Thiamin monophosphate (TMP), 485–87, 490, 498
Thiamin triphosphate (TTP), 484, 487, 498, 505
in the brain, 488, 489
Thiaminase, 490
Thrombosis
and warfarin, 588
Tissue(s)
animal
molybdenum enzymes in, 403, 404
copper uptake by, 239
distribution
of fatty acids, 519–21
ischemia-induced injury to, 405
magnesium in, 439
measuring copper levels in, 249–50
molybdenum in, 415–16
phosphate in, 122–23, 140
pterins in, 196
repair
and cachectin, 598–99
Tobacco
and carcinogenesis, 107
Total parenteral nutrition (TPN)
and chromium deficiency, 545–47
and copper deficiencies, 236
dose of phosphate for, 138
and fatty acid depletion, 533
and hypophosphatemia and phosphate depletion syndrome, 129–30
and molybdenum deficiency, 419–20
phosphorus requirements in, 130
Trace element levels
analysis of, 246
measurement of, 251–52
Trace minerals
in hair, 553–54
Tracer doses
of nutrient proteins, 333
Tracers
in placental and fetal metabolism studies, 46

Transferrin
and chromium absorption and transport, 555–56
Triglyceride
and milk synthesis, 68–69
Tumor lysis syndrome
and hyperphosphatemia, 139, 141
Tumor promotion
in carcinogenesis, 168
and dietary fat, 171–79
Turner's syndrome, 261

U

Urea production
fetal, 56
Urinary excretion
of copper, 251
Urinary phosphate losses
and phosphate depletion, 133
Urinary pterins
and BH_4 deficiency, 194–95
Urine
chromium in, 552–53, 554
USDA
"turf war" between HEW and, 5
Uterus
metabolic needs of the pregnant, 48–50
uptake of nutrients by, 44

V

Vegetables
and colon cancer, 169–70
Vimentin
in olfactory receptor cells, 24–25
Vinyl chloride
and cancer, 101, 102, 108
Vita-Lite fluorescent tubes, 388
Vitamin A
and cancer reduction, 171
and carcinogenesis, 168
and esophageal carcinogenesis, 110–11
fortification of sugar with, 6
Vitamin B_6
and lymphocyte growth, 87–88, 92–93
Vitamin C
and carcinogenesis, 168
and esophageal carcinogenesis, 110–11
Vitamin D
and artificial light sources, 387–88
and calcium and phosphate levels in the blood, 126–27
deficiency in children and adults, 388–91
enhances phosphate absorption, 124, 125
and environmental factors, 391–93
epidemiology for, 388–93
and magnesium absorption, 431
and magnesium deficiency, 440–41
malabsorption of, 131
metabolites
and phosphate depletion syndrome, 136
minimum daily requirements, 393
oral doses of large quantities, 393
oral ingestion of, 394
seasonal variation of, 391–92, 393
and sunlight, 375–95
two forms of, 377
Vitamin D_3
cutaneous production of, 382–86
photobiology of, 378–80
photodegradation of, 387, 394
Vitamin E
biochemistry of, 352–54
and cancer reduction, 171
clinical features of deficiency disorders, 359–61
deficiency, 351–69
histopathology and electrophysiology of, 361–64
isolated deficiency, 358–59, 361, 363–64, 368–69
physiology of, 354–55
treatment of deficiency, 366–69
Vitamin K
bone proteins, 565–80
and warfarin for blood coagulation, 574–77, 579–80
and warfarin treatment, 576–79
Vitamins
and dietary fiber, 318
and lymphocyte growth, 88–90
Viviparity
evolution in mammals, 289–90

W

Warfarin
and bone Gla protein, 565–66, 573–76, 579–80
prophylaxis, 579–80
and vitamin K for blood coagulation, 574–77, 579–80
and vitamin K treatment, 576–79
Water hardness
and heart disease, 444–45
Weight loss
and cachectin, 593–94
Wernicke-Korsakoff syndrome, 484, 485, 495–97, 502, 503
Wernicke's encephalopathy, 484, 485, 502–4
Wheat bran, 305–6, 310–11
Wilson disease, 241
zinc therapy of, 239
Wistar Kyoto rat, 159
Women, Infant, and Children (WIC) supplemental feeding program, 5–6, 8
Wound healing
and cachectin, 598–99

X

Xanthine dehydrogenase, 402–5, 410, 411
biological function of, 406
and molybdenum cofactor, 414
Xanthine oxidase, 402–5, 415
deficiency, 407, 412
intestinal, 406–7

Y

Yeast
and chromium, 544, 545, 548–51, 556
and thiamin, 485, 487

Z

Zellweger's syndrome, 521
Zinc
and copper deficiency, 236, 246
and copper interaction, 253
and esophageal carcinogenesis, 110–11
intake
and copper absorption, 239
Zucker fatty rat, 157–59, 162